Group 1 - The leading medical ETF (560260) recorded a financing buy of 529,700 yuan and a financing repayment of 383,700 yuan on October 31, resulting in a net financing buy of 145,900 yuan over the last three trading days [1] - The financing balance reached 4,431,000 yuan, reflecting a 3.41% increase compared to the previous day [2][3] - The net financing buy for the last three trading days totaled 1,458,800 yuan, indicating a consistent upward trend in investor interest [1][2] Group 2 - The financing balance on October 30 was 4,285,000 yuan, with a net financing buy of 565,000 yuan, marking a 15.19% increase from the previous day [2][3] - On October 29, the financing balance was 3,720,000 yuan, with a net financing buy of 747,800 yuan, showing a significant 25.16% increase [2][3] - The financing balance has shown a steady increase over the past five trading days, with the lowest balance recorded at 2,698,900 yuan on October 27 [2][3]

Group 1 - The leading medical ETF (560260) had a financing buy of 1.5037 million yuan and a financing repayment of 0.9387 million yuan, resulting in a net financing buy of 0.565 million yuan and a financing balance of 4.285 million yuan as of October 30, 2025 [1] - The net financing buy over the last three trading days totaled 1.5861 million yuan [1] - The financing balance increased by 15.19% compared to the previous day [3] Group 2 - The financing net buy on October 29 was 0.7478 million yuan, and the financing balance was 3.72 million yuan [2] - On October 28, the financing net buy was 0.2733 million yuan, with a financing balance of 2.9722 million yuan [2] - The financing balance on October 27 was 2.6989 million yuan, with a net buy of 0.1685 million yuan [2]

Core Viewpoint - The Hong Kong stock market experienced a slight decline, but the innovative drug sector showed significant movement, with Innovent Biologics surging 17% in a single day, leading to a strong rebound in related ETFs [1] Group 1: Market Performance - The largest thematic ETF in the Hong Kong market, the Hong Kong Innovative Drug ETF (513120), was the most actively traded, with a turnover rate exceeding 38% and a transaction volume close to 40 billion yuan by 11:30 AM [1] - The surge in innovative drugs is attributed to multiple industry catalysts, enhancing market confidence [1] Group 2: Industry Catalysts - The China National Medical Products Administration issued 11 innovative drug approvals at the end of May, boosting expectations for commercialization among pharmaceutical companies [1] - High-quality research results from domestic innovative drugs were showcased at the American Society of Clinical Oncology (ASCO) and American College of Rheumatology (ACR) meetings, validating the value of leading pharmaceutical pipelines and business development capabilities [1] Group 3: Investment Strategy - Investors are encouraged to construct a strategy that includes the Hong Kong Innovative Drug ETF (513120), Medical ETF Leader (560260), and Pharmaceutical and Health ETF (159938) to capture opportunities across the entire innovative drug supply chain [1] - The three ETFs form a closed loop: the Hong Kong Innovative Drug ETF addresses R&D breakthroughs, the Medical ETF Leader focuses on industrialization, and the Pharmaceutical and Health ETF captures commercialization [2] Group 4: ETF Details - The Hong Kong Innovative Drug ETF (513120) tracks the China Securities Hong Kong Innovative Drug Index, with a current P/E ratio of 27 times and a valuation at the 18th percentile historically [4] - The Medical ETF Leader (560260) focuses on medical devices and services, with a P/E ratio of 31 times and a valuation at the 20th percentile historically [4] - The Pharmaceutical and Health ETF (159938) covers the pharmaceutical and health industry, with a P/E ratio of 35 times and a valuation at the 43rd percentile historically [4]